1. Designing a light-activated recombinant alpha hemolysin for colorectal cancer targeting

Siamak Alizadeh, Abolfazl Barzegari, Abolghasem Esmaeili*, Yadollah Omidi*

Bioimpacts. 2020;10(3): 187-193. doi: 10.34172/bi.2020.23

PMCID: PMC7416006 PMID: 32793441 Scopus ID: 85089711371

Article

PDF

Full Text

XML

Cited By:

E. coli Nissle 1917 (EcN) is proposed as an appropriate light-activated vehicle for delivery of anticancer agents to the cancer cells/tissues such colorectal cancer.

Original Research

2. Cell cycle arrest and anti-cancer potential of probiotic Lactobacillus rhamnosus against HT-29 cancer cells

Najme Dehghani , Farzaneh Tafvizi* , Parvaneh Jafari

BioImpacts. 2021;11(4): 245-252. doi: 10.34172/bi.2021.32

PMCID: PMC8494254 PMID: 34631486 Scopus ID: PMC8494254

Article

PDF

Full Text

XML

Cited By:

The supernatant of probiotic L. rhamnosus has a great potential to inhibit the proliferation of HT-29 cells and the induction of apoptosis.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons